Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Amylyx Pharmaceuticals, Inc.
CEO
Mr. Joshua B. Cohen
Employees
237
Industry
Biotechnology
Sector
Healthcare
Market cap
$229M
Company details
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Revenue
CoG
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$294.22M
Cost of goods (CoG)
-$18.90M
Gross profit (GP)
$275.32M
Operating expense (OE)
-$283.04M
Research and development (R&D)
-$106.09M
General and administrative (G&A)
-$176.96M
Operating income (OI)
-$7.72M
Other income expense (OIE)
-$5.36M
Pretax income (PI)
$5.70M
Tax (TAX)
-$3.86M
Net income (NI)
$1.84M
Stock vs Industry average
-
Industry average
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$0.03
Margin profit
-55.52%
52 week low
$1.62
52 week high
$19.57
50-day simple moving average
$3.08
200-day simple moving average
$2.96
Percent held by insiders
14.35%
Percent held by institutions
86.49%
Dividend yield
0.00%
